← All trials
NCT05398796
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2022
- Primary completion
- Jun 24, 2024
- Completion date
- Jun 24, 2024
- First posted
- Jun 1, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 50
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Overall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Official
- Moderna TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.